Lexington, Mass. – March 22, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for recombinant ADAMTS13 (SHP655 - historically known as BAX930) for treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP) in patients with a constitutional deficiency of the von Willebrand factor-cleaving (VWF) protease ADAMTS13. Hereditary thrombotic thrombocytopenic purpura is a life-threatening congenital disease caused by a deficiency in the enzyme ADAMTS13 which can cause clotting in the microvasculature with associated organ morbidities.1,4
"As the leader in rare disease, Shire is committed to providing an innovative pipeline of world class therapeutics to the patients that need them most,” said Philip J. Vickers, Ph.D., Head of R&D, Shire. “Today’s confirmation from FDA that SHP655 for hereditary thrombotic thrombocytopenic purpura has been granted Fast Track designation reaffirms the significant unmet need that exists for this patient population and provides hope of reducing morbidity in patients with hTTP.”
FDA’s Fast Track designation is supported by preclinical data and a Phase 1 study. The FDA’s Fast Track process is designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. However, it does not guarantee that the FDA will ultimately approve SHP655 or the timing of any such approval.
Shire will initiate its Phase 3 trial with SHP655 as a randomized, open-label, 2-period crossover study with a single arm continuation to evaluate the safety and efficacy of SHP655 in the treatment and prevention of acute TTP events in patients with severe hereditary ADAMTS13 deficiency.2 This global study will be conducted in the U.S., Europe, and Japan.3
Additional information on the SHP655 Phase 1 study can be found on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02216084?term=BAX930&rank=1
The Phase 1 data included results from 15 patients with severe hTTP who completed the multicenter study. Each patient received a single dose of SHP655 in one of three dosing cohorts. The activity PK parameters, including terminal half-life, were comparable to those estimated from fresh frozen plasma (FFP) studies and demonstrated dose proportionality with respect to Cmax and AUC.4 No serious adverse events were reported. In the highest dosing cohort, three subjects reported three possibly related adverse events, nausea, flatulence and decreased VWF antigen and VWF activity; all of these reported adverse events resolved without medication. Immunogenicity tests performed at screening, pre-dose and upon study completion, were negative in all subjects.4
About Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)
Hereditary Thrombotic Thrombocytopenic Purpura (hTTP) is a life-threatening congenital disease caused by a deficiency in the enzyme ADAMTS13. This deficiency can cause clotting in the microvasculature with associated organ morbidities.1,4 Mortality is high if untreated. Currently, between 3,000 to 4,000 patients worldwide have hTTP5, and there are no approved treatment options although various other treatments are used off label and have a range of severe complications for patients.6 If approved, SHP655 (historically known as BAX 930) would be the world's first recombinant ADAMTS13 enzyme replacement therapy.
SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates.
|Ian Karpfirstname.lastname@example.org||+1 781 482 9018|
|Robert Coatesemail@example.com||+44 1256 894874|
|Debbi Fordfirstname.lastname@example.org||+1 617 949 9083|
|Molly Poarchemail@example.com||+1 312 897 3244|
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products, are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, the following:
a further list and description of risks, uncertainties and other matters can be found in Shire’s most recent Annual Report on Form 10-K and in Shire’s subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in “ITEM 1A: Risk Factors”, and in subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire’s website.
All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
1 Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract.Res.Clin.Haematol. 2001;14:437-454.
2 Clinical Study Protocol; A phase 3, randomized, controlled study of prophylactic and on-demand treatment of hTTP with BAX 930 (rADAMTS13), February 2017; 1-104.
3 Clinical Development Plan (SHP655); BAX 930/ rADAMTS13 Hereditary Thrombotic Thrombocytopenic Purpura. July 2015; 1-4.
4 Full Clinical Study Report 281101. BAX930 (rADAMTS13). June 2016; 1-238.
5 Mansouri Taleghani M. et al. Hereditary thrombotic thrombo -cytopenic purpura and the hereditary TTP registry. Schattauer 2013; 1-6.
6 Pandey S, Vyas G. Adverse effects of plasma transfusion; TRANSFUSION 2012;52:65S-79S